Matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in patients with relapsing–remitting multiple sclerosis treated with interferon beta

Keegan, 2002, Multiple sclerosis, Annu Rev Med, 53, 285, 10.1146/annurev.med.53.082901.103909

Compston, 2004, The pathogenesis and basis for treatment in multiple sclerosis, Clin Neurol Neurosurg, 106, 246, 10.1016/j.clineuro.2004.02.007

Bar-Or, 1999, Molecular pathogenesis of multiple sclerosis, J Neuroimmunol, 100, 252, 10.1016/S0165-5728(99)00193-9

Hartung, 2000, The role of matrix metalloproteinases in autoimmune damage to the central and peripheral nervous system, J Neuroimmunol, 107, 140, 10.1016/S0165-5728(00)00225-3

Rosenberg, 2002, Matrix metalloproteinases and neuroinflammation in multiple sclerosis, Neuroscientist, 8, 586, 10.1177/1073858402238517

Yong, 2001, Metalloproteinases in biology and pathology of the nervous system, Nat Rev Neurosci, 2, 502, 10.1038/35081571

Opdenakker, 2003, Functional roles and therapeutic targeting of gelatinase B and chemokines in multiple sclerosis, Lancet Neurol, 2, 747, 10.1016/S1474-4422(03)00587-8

Yong, 1998, Matrix metalloproteinases and diseases of the CNS, Trends Neurosci, 21, 75, 10.1016/S0166-2236(97)01169-7

Oh, 1999, Matrix metalloproteinase-9/gelatinase B is required for process outgrowth by oligodendrocytes, J Neurosci, 19, 8464, 10.1523/JNEUROSCI.19-19-08464.1999

Harkness, 2000, Central retinal vein occlusion complicating treatment with intravenous immunoglobulin, Eye, 14, 662, 10.1038/eye.2000.163

Clements, 1997, Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor, J Neuroimmunol, 74, 85, 10.1016/S0165-5728(96)00210-X

Dubois, 1999, Gelatinase B in multiple sclerosis and experimental autoimmune encephalomyelitis, Acta Neurol Belg, 99, 53

Nagase, 1999, Matrix metalloproteinases, J Biol Chem, 274, 21491, 10.1074/jbc.274.31.21491

Brew, 2000, Tissue inhibitors of metalloproteinases: evolution, structure and function, Biochim Biophys Acta, 1477, 267, 10.1016/S0167-4838(99)00279-4

Lee, 1999, Serum gelatinase B TIMP-1 and TIMP-2 levels in multiple sclerosis. A longitudinal clinical and MRI study, Brain, 122, 191, 10.1093/brain/122.2.191

Waubant, 2003, IFNbeta lowers MMP-9/TIMP-1 ratio, which predicts new enhancing lesions in patients with SPMS, Neurology, 60, 52, 10.1212/WNL.60.1.52

Rosenberg, 1996, Effect of steroids on CSF matrix metalloproteinases in multiple sclerosis: relation to blood–brain barrier injury, Neurology, 46, 1626, 10.1212/WNL.46.6.1626

Yong, 2002, Differential mechanisms of action of interferon-beta and glatiramer aetate in MS, Neurology, 59, 802, 10.1212/WNL.59.6.802

Karabudak, 2004, Effect of interferon beta-1a on serum matrix metalloproteinase-9 (MMP-9) and tissue inhibitor of matrix metalloproteinase (TIMP-1) in relapsing remitting multiple sclerosis patients. One year follow-up results, J Neurol, 251, 279, 10.1007/s00415-004-0285-7

Liuzzi, 2002, Intrathecal synthesis of matrix metalloproteinase-9 in patients with multiple sclerosis: implication for pathogenesis, Mult Scler, 8, 222, 10.1191/1352458502ms800oa

Kurtzke, 1983, Rating neurologic impairment in multiple sclerosis: an expanded disability status scale (EDSS), Neurology, 33, 1444, 10.1212/WNL.33.11.1444

Poser, 1983, New diagnostic criteria for multiple sclerosis: guidelines for research protocols, Ann Neurol, 13, 227, 10.1002/ana.410130302

Leppert, 1996, Interferon beta-1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis, Ann Neurol, 40, 846, 10.1002/ana.410400606

Waubant, 1999, Serum MMP-9 and TIMP-1 levels are related to MRI activity in relapsing multiple sclerosis, Neurology, 53, 1397, 10.1212/WNL.53.7.1397

Ozenci, 1999, Metalloproteinases and their tissue inhibitors in multiple sclerosis, J Autoimmun, 12, 297, 10.1006/jaut.1999.0285

Leppert, 1998, Matrix metalloproteinase-9 (gelatinase B) is selectively elevated in CSF during relapses and stable phases of multiple sclerosis, Brain, 121, 2327, 10.1093/brain/121.12.2327

Lichtinghagen, 1999, Expression of matrix metalloproteinase-9 and its inhibitors in mononuclear blood cells of patients with multiple sclerosis, J Neuroimmunol, 99, 19, 10.1016/S0165-5728(99)00094-6

Avolio, 2003, Serum MMP-2 and MMP-9 are elevated in different multiple sclerosis subtypes, J Neuroimmunol, 136, 46, 10.1016/S0165-5728(03)00006-7

Gijbels, 1992, Gelatinase in the cerebrospinal fluid of patients with multiple sclerosis and other inflammatory neurological disorders, J Neuroimmunol, 41, 29, 10.1016/0165-5728(92)90192-N

Mandler, 2001, Matrix metalloproteinases and tissue inhibitors of metalloproteinases in cerebrospinal fluid differ in multiple sclerosis and Devic's neuromyelitis optica, Brain, 124, 493, 10.1093/brain/124.3.493

Yushchenko, 2000, Matrix metalloproteinase-9 (MMP-9) in human cerebrospinal fluid (CSF): elevated levels are primarily related to CSF cell count, J Neuroimmunol, 110, 244, 10.1016/S0165-5728(00)00339-8

Cuzner, 1999, Plasminogen activators and matrix metalloproteases, mediators of extracellular proteolysis in inflammatory demyelination of the central nervous system, J Neuroimmunol, 94, 1, 10.1016/S0165-5728(98)00241-0

Leppert, 2001, Matrix metalloproteinases: multifunctional effectors of inflammation in multiple sclerosis and bacterial meningitis, Brain Res Rev, 36, 249, 10.1016/S0165-0173(01)00101-1

Ozenci, 2000, Multiple sclerosis: pro- and anti-inflammatory cytokines and metalloproteinases are affected differentially by treatment with IFN-beta, J Neuroimmunol, 108, 236

Waubant, 2001, IFN-beta1a may increase serum levels of TIMP-1 in patients with relapsing–remitting multiple sclerosis, J Interferon Cytokine Res, 21, 181, 10.1089/107999001750133230

Dubois, 2003, Serum gelatinase B/MMP-9 in primary progressive multiple sclerosis patients treated with interferon-beta-1a, J Neurol, 250, 1037, 10.1007/s00415-003-0110-8

Yushchenko, 2003, Interferon-beta-1 b decreased matrix metalloproteinase-9 serum levels in primary progressive multiple sclerosis, J Neurol, 250, 1224, 10.1007/s00415-003-0191-4

Nelissen, 2003, Gelatinase B/matrix metalloproteinase-9 cleaves interferon-beta and is a target for immunotherapy, Brain, 126, 1371, 10.1093/brain/awg129

Brundula, 2002, Targeting leukocyte MMPs and transmigration: minocycline as a potential therapy for multiple sclerosis, Brain, 125, 1297, 10.1093/brain/awf133

Popovic, 2002, Inhibition of autoimmune encephalomyelitis by a tetracycline, Ann Neurol, 51, 215, 10.1002/ana.10092

Metz, 2004, Minocycline reduces gadolinium-enhancing magnetic resonance imaging lesions in multiple sclerosis, Ann Neurol, 55, 756, 10.1002/ana.20111